Regentis Biomaterials (Regentis Biomaterials) EPS (Diluted) : $-0.37 (TTM As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Regentis Biomaterials EPS (Diluted)?

Regentis Biomaterials's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was $-0.28. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.37.

Regentis Biomaterials's EPS (Basic) for the six months ended in Jun. 2023 was $-0.28. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.37.

Regentis Biomaterials's EPS without NRI for the six months ended in Jun. 2023 was $-0.28. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.36.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Regentis Biomaterials EPS (Diluted) Historical Data

The historical data trend for Regentis Biomaterials's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regentis Biomaterials EPS (Diluted) Chart

Regentis Biomaterials Annual Data

Trend

Dec20

Dec21

Dec22

EPS (Diluted)

-0.04

-0.45

-0.12

Regentis Biomaterials Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EPS (Diluted)	Get a 7-Day Free Trial			-	-0.45	-0.04	-0.08	-0.28

Competitive Comparison of Regentis Biomaterials's EPS (Diluted)

For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regentis Biomaterials's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's PE Ratio distribution charts can be found below:

* The bar in red indicates where Regentis Biomaterials's PE Ratio falls into.

Regentis Biomaterials EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Regentis Biomaterials's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-1.383	-	0)	/	11.561
	=	-0.12

Regentis Biomaterials's Diluted EPS for the quarter that ended in Jun. 2023 is calculated as

Diluted EPS (Q: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-3.253	-	0)	/	11.561
	=	-0.28

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.37

Regentis Biomaterials (NAS:RGNT) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Regentis Biomaterials EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Regentis Biomaterials's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Regentis Biomaterials (Regentis Biomaterials) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Regentis Biomaterials Corp (NAS:RGNT) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Ha’ilan Street, P.O. Box 260, Northern Industrial Zone, Or-Akiva, ISR, 306000

Website

http://www.regentis.co.il

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

Regentis Biomaterials (Regentis Biomaterials) Headlines

No Headlines